Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
uqt5jNMzvn9NbLpS
Listen
